Core Viewpoint - The article highlights the significant achievement of Huahui Anjian, a Chinese pharmaceutical company, in developing its first fully innovative drug, Libeweita, which marks a milestone in China's pharmaceutical history and represents a shift towards original innovation in the industry [4][13]. Group 1: Company Background and Development - Huahui Anjian was founded in 2015 by researchers from the Beijing Institute of Life Sciences, including Li Wenhui and Sui Jianhua, amidst a supportive environment for drug review reforms initiated by the Chinese government [4][6]. - The company has grown from a small startup with a few employees to a prominent player with over a hundred staff and multiple clinical-stage pipelines [4][6]. - The approval of Libeweita, a monoclonal antibody drug for chronic hepatitis D, is a result of over a decade of research and development, beginning with Li Wenhui's discovery of the hepatitis B virus receptor in 2012 [6][8]. Group 2: Drug Development Process - The development of Libeweita involved extensive clinical trials, starting with Phase I trials in 2019, which demonstrated good safety profiles [8][9]. - The drug received "breakthrough therapy" designation from the National Medical Products Administration of China in April 2023, indicating its potential to address unmet medical needs [10][13]. - Libeweita was officially approved for market release on January 23, 2026, after a rigorous clinical trial process that showcased its efficacy in blocking the infection process of hepatitis viruses [13][18]. Group 3: Market Potential and Future Plans - There are approximately 12 million global hepatitis D virus infections, with China potentially having over 600,000 cases, indicating a significant market need for effective treatments [18][21]. - Following the drug's launch, Huahui Anjian aims to expand its international presence, particularly in countries along the "Belt and Road" initiative where hepatitis D is prevalent [19][20]. - The company plans to offer Libeweita at different price points in various markets, ensuring accessibility while maintaining a global pricing strategy [20][21]. Group 4: Company Culture and Challenges - Huahui Anjian fosters a culture of equality and open communication, which is rooted in its origins at the Beijing Institute of Life Sciences [24][25]. - The company faced significant challenges during the COVID-19 pandemic and subsequent market downturn, leading to staff reductions and financial strain [28][29]. - Despite these challenges, the company secured crucial funding in March 2024, allowing it to continue its operations and prepare for the launch of Libeweita [28][29].

Core Viewpoint - The article highlights the collaborative journey of two prominent scientists, Li Wenhui and Sui Jianhua, who have made significant contributions to the field of virology and antibody engineering, culminating in the development of the first monoclonal antibody drug for viral hepatitis, Libeweita [3][4][12]. Group 1: Scientific Contributions - Li Wenhui was the first to discover the receptor for the SARS virus and the hepatitis B virus, while Sui Jianhua was the first to design human antibodies against these viruses [3][4]. - During the COVID-19 pandemic, they collaborated on a broad-spectrum anti-COVID drug, although it was not developed further due to the pandemic's resolution [3][4]. - The monoclonal antibody drug Libeweita is set to be approved in January 2026, marking a significant milestone in the treatment of viral hepatitis [3][4]. Group 2: Personal and Professional Journey - Li and Sui met at Lanzhou University over 30 years ago and have since maintained a close professional relationship, often engaging in scientific debates that drive their research forward [11][15]. - They both pursued postdoctoral research at Harvard University, where their paths converged in the study of viral infections and antibody development [6][10]. - Their partnership is characterized by a seamless integration of their respective expertise, with Li focusing on the mechanisms of viral infections and Sui on antibody engineering [12][17]. Group 3: Company Formation and Vision - In 2015, they co-founded Huahui Anjian, a company aimed at developing innovative drugs for liver diseases, reflecting their shared scientific aspirations [16]. - Li primarily handles basic scientific discoveries while Sui manages the company's operations and clinical trials, showcasing their complementary roles [16][17]. - Their discussions often revolve around company matters, with a dynamic of questioning and critical thinking that fosters innovation [16][17].

Core Viewpoint - The article highlights the collaborative journey of two prominent scientists, Li Wenhui and Sui Jianhua, who have made significant contributions to the field of virology and antibody engineering, culminating in the development of the first monoclonal antibody drug for viral hepatitis, Lebevetab [1][2][6]. Group 1: Background and Education - Li Wenhui and Sui Jianhua met at Lanzhou University over 30 years ago and have since pursued parallel academic paths, including postdoctoral research at Harvard University [2][3]. - Their scientific collaboration began shortly after their marriage, leading to groundbreaking discoveries in the fields of SARS and hepatitis B [1][4]. Group 2: Research Contributions - Li Wenhui was the first to identify the receptor for the SARS virus, while Sui Jianhua developed the first human-derived antibody against SARS [3][6]. - Sui Jianhua discovered a broad-spectrum neutralizing antibody for the H1N1 influenza virus, which has implications for future antiviral treatments and vaccine development [5][6]. - In 2012, Li Wenhui identified the hepatitis B virus receptor, a significant breakthrough after decades of research [6][8]. Group 3: Company Formation and Drug Development - In 2015, the couple co-founded Huahui Anjian, a biopharmaceutical company aimed at developing innovative treatments for liver diseases [11][12]. - The company focuses on transforming scientific discoveries into practical applications, with Li Wenhui handling basic scientific research and Sui Jianhua managing operations and clinical trials [11][12]. Group 4: Personal Dynamics and Work Ethic - The couple is known for their intense debates on scientific topics, which they view as a means of intellectual growth rather than conflict [11][13]. - Their complementary skills—Li Wenhui's critical thinking and Sui Jianhua's practical application—allow for seamless collaboration in their research endeavors [8][11].

Core Insights - The article highlights the approval and significance of the first monoclonal antibody drug for chronic hepatitis D, named Libebweita, developed by Chinese scientists Li Wenhui and Sui Jianhua, marking a milestone in China's pharmaceutical innovation [2][3][4]. Company Development - Huahui Anjian, co-founded in 2015, has evolved from a small startup to a prominent company with over a hundred employees and multiple clinical pipelines, benefiting from supportive government policies and capital [3][4]. - The company has successfully transitioned from basic research to the commercialization of original drugs, a rare achievement in China's pharmaceutical history [3][4]. Drug Development Process - Libebweita's development began with Li Wenhui's discovery of the hepatitis B virus receptor in 2012, which laid the groundwork for creating effective treatments for hepatitis B and D [4][5]. - The drug was prioritized for chronic hepatitis D due to the urgent need for effective treatments, as patients with co-infection face more severe health risks [5][6]. - Clinical trials showed promising results, with Libebweita demonstrating good safety and antiviral activity during phase I and II trials [6][8]. Market Potential and Future Plans - The global hepatitis D infection rate is approximately 12 million, with China potentially having over 600,000 cases, indicating a significant market opportunity for Libebweita [16]. - The company aims to expand internationally, particularly in countries along the Belt and Road Initiative, where hepatitis D is prevalent [18][19]. - Huahui Anjian plans to position Libebweita competitively in both domestic and international markets, with a focus on affordability in emerging markets [19]. Cultural and Operational Insights - The company fosters a culture of equality and open communication, which is rooted in its origins at the Beijing Institute of Life Sciences [22][23]. - The leadership emphasizes the importance of innovation and risk-taking in drug development, reflecting a commitment to original research rather than following existing models [21][24].

Macro Economy - The People's Bank of China will continue to promote global financial governance reform and international financial cooperation while stabilizing domestic growth, aiming for a high level of openness in the financial services industry and markets by 2026 [2] - Brazil announced visa exemptions for certain short-term categories for Chinese citizens, leading to a significant increase in tourism-related searches, with cities like Rio de Janeiro, São Paulo, and Brasília seeing over a fivefold increase in search volume compared to the previous week [2] - Monitoring by the National Bureau of Statistics shows that in mid-January 2026, 29 out of 50 important production materials saw price increases, with live pig prices rising by 0.4 yuan per kilogram, a 3.2% increase [2] - The National Internet Information Office is drafting a guideline for the classification and grading of financial information services data, which will be open for public consultation [2] Investment News - The Beijing Stock Exchange has seen a "good start" in new stock markets in 2026, with three companies going to meetings, two listing, and two starting fundraising this week. The total frozen funds for new stocks this year have exceeded 800 billion yuan, with Aisheren setting a historical record [4] - As of January 24, 2026, eight banks in the A-share market have reported positive growth in net profit, with notable trends including steady asset expansion, improved non-performing loan ratios, and increased provisioning efforts [4] - Fund holdings from the fourth quarter of 2025 show a preference for low-risk products, with short-term bond ETFs being the top holdings, while gold ETFs were reduced in favor of gold stock ETFs [4] Company Developments - Commercial aerospace leader CASIC has completed its IPO counseling and entered the acceptance process on January 16 [7] - Apple has initiated a significant price reduction for its new iPhone Air, with a discount of 2,500 yuan, bringing the price down to 5,499 yuan [7] - BYD plans to sell 1.3 million vehicles outside China in 2026, up from 1.05 million in overseas deliveries last year [7] - Innovative pharmaceutical company Huahui Anjian has received approval for its first-in-class drug, a hepatitis D treatment, filling a gap in the domestic market [7] International Dynamics - Finnish Prime Minister Orpo arrived in Beijing for a four-day visit, bringing along executives from over 20 companies in sectors such as machinery, clean energy, and food [8] - A trilateral meeting involving Ukraine, the U.S., and Russia made some progress on military issues but did not reach any agreements on territorial matters [8] - U.S. President Trump announced expectations of gaining sovereignty over areas of Greenland where U.S. military bases are located, claiming negotiations are progressing well [8]

Core Viewpoint - The approval of the innovative drug Lebeweta Monoclonal Antibody Injection by the National Medical Products Administration marks a significant advancement in the treatment of viral hepatitis, particularly for chronic hepatitis B and D patients in China [1][2]. Group 1: Drug Development and Approval - The drug Lebeweta Monoclonal Antibody is the world's first antibody drug approved for the treatment of viral hepatitis, filling a significant gap in the domestic market for hepatitis D treatment [1]. - The research leading to this drug was based on a breakthrough discovery by Li Wenhui's team at the Beijing Institute of Life Sciences, identifying the sodium-taurocholate co-transporting polypeptide (NTCP) as the key receptor for hepatitis B and D viruses [1][2]. Group 2: Clinical Significance - The drug acts as a "molecular lock" that prevents the hepatitis virus from entering liver cells, thereby blocking the infection pathway at its source [2]. - Clinical trials have shown that Lebeweta Monoclonal Antibody has significant efficacy, particularly benefiting patients with chronic hepatitis D and B-related liver cirrhosis [2]. Group 3: Future Aspirations - The company, Huahui Anjian, continues to advance its pipeline of innovative drugs targeting hepatitis B, with the ultimate goal of achieving a cure for hepatitis B [2].